Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Cutaneous eruptions by new therapies against hepatitis C virus infection. Not as common as we presumed

Cutaneous eruptions by new therapies against hepatitis C virus infection. Not as common as we... Antiviral treatment for patients with hepatitis C virus (HCV) infection has undergone a massive revolution in the last five years, since the development of HCV direct‐acting antiviral agents (DAAs). Several combinations of DAAs regimens have been reported to have a higher effectiveness and tolerability compared to IFN‐based regimens. The first available DAAs were the HCV NS3/4A protease inhibitors, telaprevir and boceprevir. These newer HCV medications have been found to have a much greater response rate than the classic therapy. This has drawn the attention of specialist doctors, including dermatologists. In fact, in 2014, Klujszo et al. noticed the link between skin rashes and protease inhibitors during HCV therapy, which has been described in around 21% of patients using telaprevir. The high rate of adverse effects associated with this therapy was a common cause of withdrawal, limiting the possibility of achieving sustained virologic response in HCV‐infected patients. It has not been proven that newer protease inhibitors such as boceprevir increase the risk of skin rashes, as Carrascosa et al. explain in their article. There is a new combination of drugs, Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir (Viekirax® and Exviera®) that is worth discussing, following our experience with a patient who had a generalized http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png International Journal of Dermatology Wiley

Cutaneous eruptions by new therapies against hepatitis C virus infection. Not as common as we presumed

Download PDF
2 pages

Loading next page...
1
 
/lp/wiley/cutaneous-eruptions-by-new-therapies-against-hepatitis-c-virus-EMSZD5yRIv

References (9)

Publisher
Wiley
Copyright
International Journal of Dermatology © 2018 International Society of Dermatology
ISSN
0011-9059
eISSN
1365-4632
DOI
10.1111/ijd.13882
Publisher site
See Article on Publisher Site

Abstract

Antiviral treatment for patients with hepatitis C virus (HCV) infection has undergone a massive revolution in the last five years, since the development of HCV direct‐acting antiviral agents (DAAs). Several combinations of DAAs regimens have been reported to have a higher effectiveness and tolerability compared to IFN‐based regimens. The first available DAAs were the HCV NS3/4A protease inhibitors, telaprevir and boceprevir. These newer HCV medications have been found to have a much greater response rate than the classic therapy. This has drawn the attention of specialist doctors, including dermatologists. In fact, in 2014, Klujszo et al. noticed the link between skin rashes and protease inhibitors during HCV therapy, which has been described in around 21% of patients using telaprevir. The high rate of adverse effects associated with this therapy was a common cause of withdrawal, limiting the possibility of achieving sustained virologic response in HCV‐infected patients. It has not been proven that newer protease inhibitors such as boceprevir increase the risk of skin rashes, as Carrascosa et al. explain in their article. There is a new combination of drugs, Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir (Viekirax® and Exviera®) that is worth discussing, following our experience with a patient who had a generalized

Journal

International Journal of Dermatology – Wiley

Published: Jan 1, 2018

There are no references for this article.